9 ms·
What this article misses is that even with a price tag of more than $1M, many of these therapies will save the system money. They kind of gloss over it when ta
by refurb 8y ago
What this article misses is that even with a price tag of more than $1M, many of these therapies will save the system money.
They kind of gloss over it when talking about Zolgensma, but the current treatment, Spinraza, costs ~$750K in the first year and $375K every year after. So even by year 2, you've already spent one million and you pay that indefinitely.
So if Zolgensma shows 5 years of efficacy and Zolgensma costs $2M, it's already 10% cheaper than current costs.
Yes of course, paying it in a lump sum is challenging, but these companies are all exploring alternative payment methods; either paying installments ($500K per year for 4 years) or performance based models (you pay me $500K, every year, until the drug stops working).
Gene therapy will certainly require a new payment plan, but it's not something the system can't handle.
- anfilt 8y agoAt that point it's probably just cheaper to get a plane ticket to a country that does not patent or enforce a patent for the treatment.
- refurb 8y agoUnlike small molecules, gene therapy isn't something that somebody can just whip up in a lab. Similar to biologics, there are often some trade secrets involved in the manufacturing that require a lot of time and money to figure out.
- tuxxy 8y agoHow can anyone think this is ethical for lifesaving medical care?
- refurb 8y agoNot sure what you mean. Are you saying it’s unethical that it’s hard to make new therapies?
- Reelin 8y agoParent is asking how it can be ethical to place such a large price tag on a lifesaving therapy if the materials themselves are cheap. It's one thing for AMD or Intel to recoup engineering costs with outlandish per-chip costs as compared to the cost of manufacturing itself. However, serious ethical questions about profit margins and recouping R&D appear once someone's life is directly tied to usage. That being said, obviously we have to fund development somehow.
- tuxxy 8y agoThis is a great comment, but I have to say my comment was rather rushed. I was implying more that the idea of trade secrets on life-saving treatment was unethical. The question of funding is an important discussion, but I was trying to discuss the trade secret details and I didn't really get my point across in the comment.
- Reelin 8y agoThat honestly hadn't occurred to me; I'm much more familiar with fields where most of the important details end up patented. I generally view all forms of intellectual property (patents, trade secrets, copyrights) as nothing more than mechanisms by which to exact funding. I suppose a trade secret would prevent circumventing IP law by heading to a more permissive jurisdiction and is potentially indefinite. But then again, if anyone ever successfully reverse engineered it (or it leaked) my understanding is you can't patent it in retrospect? So it seems like a huge risk to me. From an ethical standpoint, I'm not seeing where it would be any worse than a patent (one that's actually enforced). Unless you're concerned about the possibility of the knowledge becoming lost to humanity? Or something else? An aside: I wouldn't be optimistic about the usefulness of trade secrets on their own in the biomedical sciences. It can certainly be tedious to reverse engineer something, but my impression is that it's generally the IP laws that stop your potential competition.
- Mirioron 8y agoIt's ethical, because as a society we need to look at the long term rather than any specific treatment. It's better for us if private investors invest money into lifesaving treatments, because it means that more of them will be available earlier to people. If investors go and invest in something else then nobody's getting the benefit of the medicine. Let's say we have a disease that kills 1000 people per year. Let's look at a 40 year period. 1. No cure is researched or found in 40 years. Total death count: 40,000. 2. For the first 10 years no cure is found. After 10 years a company comes along and creates a lifesaving cure, however it's expensive - only 500 people per year can afford it. The patent on it lasts 20 years. After 20 years another company creates a generic version of it that 990 people can afford. In the first 10 years 10,000 people die, in the following 20 years another 10,000 people die, in the last 10 years 100 people die. Total death count: 20,100. 3. No cure is found in the first 20 years, then a government funded research team finds a cure. A company picks it up and creates a generic, where 99% people can afford it. In the first 20 years 20,000 people die. In the latter 20 years 200 people die. Total death count: 20,200. Being early matters in medicine. It's always easy to look at an expensive treatment and say that this should be much cheaper, but we usually don't consider that forcing investors out of healthcare means that less research will be done. This means fewer treatments and a longer time before a treatment is found.
- smacke 8y agoPlaying devil's advocate: there may be an argument that such care would not have been developed without the free-market monetary incentive. (Maybe not; maybe it would have been developed thanks to some government-funded grant. The point is: it's worth understanding what's possible and impossible in our current system.)
- deadbunny 8y agoI work for a government driven genome research company in the UK, there are many others like this across Europe. Gov funding isn't such a problem in Europe where healthcare is a government issue.
- onetimemanytime 8y agoHmmmm: The food that you ate last night might saved a life or two in Africa. Or given a child the nutrition it needs. You could have done just fine with half of what you ate...
- rayiner 8y agoIn a market-oriented society, it's unethical to put in place rules that divert capital and talent way from the development of lifesaving medical care. (And the half-ass refrain of accepting a market economy generally, but making an exception for medical care as being "too important to leave to the market" makes no sense. Unless you tamp down on the flow of capital to other industries, designating some areas as "too important" to leave to the market will simply cause capital to flee to, e.g. dating websites, leaving the "too important" industries as ghettos.) The ethical thing to do is constructing a system that maximizes the amount of lifesaving medical care at minimum cost. Doing that requires acknowledging market forces. Scientists and engineers aren't any more altruistic than anyone else. These days the incoming classes at investment banks are full of physics, biology, and chemistry majors that could easily have gotten a PhD and went to go work for NIH. In the healthcare space, there is at least the potential for making a lot of money by doing a startup with the hopes of getting acquired by one of the big pharma companies. If you take that option away--if developing lifesaving medical care is a field that nets you at best a GS-scale government job--talent and capital are going to go develop dating apps instead.
- anfilt 8y agoStill does not stop someone from trying since they now know what to look for. Also genetic synthesis has gotten cheaper and so has sequencing. Moreover a lot techniques for gene therapy are already in the literature. Moreover you have to document what it's doing or what your doing for approval (in-case of a procedure).
- dekhn 8y agogene therapy isn't something you can just whip up in a random lab and apply to people without there being dire consequences (heck, that happens even in top research institutions).
- codeulike 8y agoCRISPR's not that hard, this guy did it in his garage. Delivering it to cells is a bit harder, but not that hard unless you're talking brain cells, then the blood-brain barrier causes trouble. https://www.theguardian.com/science/2017/dec/24/josiah-zayner-diy-gene-editing-therapy-crispr-interview https://www.theguardian.com/science/2017/dec/24/josiah-zayne...
- folli 8y agoCRISPR is unrelated to Zolgensma, which uses an Adeno-associated virus to deliver a functioning version of the SMN1 gene.
- codeulike 8y agoI know. I was giving an example of modern biotech
- dekhn 8y agoanybody with a decent level of biochemical knowledge can do these things in a garage (I built a biolab in my garage and work at a lab that does CRISPR). However, the person you cited is clueless and is just kind of injecting things into his body without any really thought to efficacy or safety. There is a big difference between injecting reagents into a single human, and doing actual medicine.
- deleted 8y ago[deleted]
- deleted 8y ago[deleted]
- Palptine 8y agoTell that to the guy that tried to create HIV resistance babies in China. He had a decent lab yet both babies he created didn't have ccr5 hit: the crispr missed target.
- refurb 8y ago
- rayiner 8y agoHow many life-saving gene therapies have been developed in these countries?
- Not_a_pizza 8y agoOr a different planet!!!
- sytelus 8y agoI don't think if the question is whether large bills can be handled by distributing $1M payments over N years. The question is, should this really be costing $1M? I understand if there is a billion dollar investment by big pharma that benefits 1000 people and so there is no other way but to charge $1M. However, it appears that fundamental techniques are all same and it gets reused for hundreds or thousands different treatments. So with cost spread, the cost to patient shouldn't be $1M. If big pharma has life saving treatment and they thought they got people by their balls to pay up any ransom amount then its just wrong.
- refurb 8y agoFor many of these diseases, yes there are only a a few thousand patients in the world. And although gene therapy might be a fundamental technique, creating a gene therapy for a different disease is really hard because human biology is really hard.
- Proven 8y agoYou assume the cost of new therapies is workable simply because it’s more efficient than existing. In reality many existing therapies are all pushing the system into debt and unworkable (for example it overcharges the healthy in order to subsidize the ill). The reality is $2 million price tag may be acceptable to a multi-millionaire but unworkable for a 40 year old who makes $50K/yr. After certain age and cost level, the math just doesn’t work out. It’s tough, but once you realize you don’t have the natural right to free or subsidized healthcare, it’s easier to accept.
- skwb 8y agoBut due to insurance churn, you don’t want to be footing the bill for your competitor down the road. As an insurance manager, your unit of analysis is not healthcare system or society, but your quarterly bottom line.
- aaronbrethorst 8y agoSounds like a great argument for Medicare for All, the NHS, or other nationalized systems.
- waterhouse 8y agoOr for insurance companies to form an association that comes up with policies that would benefit all of them if they all did them, and then requires all member companies to implement them. Not sure exactly what carrot or stick they could use to ensure that any remaining insurance companies have an incentive to join the association rather than trying to free-ride off what they're doing, but one might be able to come up with something.
- aaronbrethorst 8y agoThis Wikipedia page might offer some ideas: https://en.wikipedia.org/wiki/Cartel https://en.wikipedia.org/wiki/Cartel
- ian0 8y agoOr this one: https://en.wikipedia.org/wiki/Central_bank https://en.wikipedia.org/wiki/Central_bank
- waterhouse 8y agoThe page does not list enforcement mechanisms for cartels, and in fact says: "In general, cartel agreements are economically unstable in that there is an incentive for members to cheat by selling at below the agreed price or selling more than the production quotas set by the cartel (see also game theory). This has caused many cartels that attempt to set product prices to be unsuccessful in the long term. Empirical studies of 20th century cartels have determined that the mean duration of discovered cartels is from 5 to 8 years." Come to think of it, the general idea is "If you, as an insurance company, foot the bill for these treatments with long-term benefits for your clients, this will cost $X, but save you $Y and other nearby insurance companies $Z in the future. Therefore, we the association will pay you $z < $Z to do it, and by assumption $Y+$Z > $X, so there should exist values of $z that make this profitable for both parties (anything between $X-$Y and $Z)." The carrot is the payment of $z. In terms of whether this association could become a price-fixing cartel... It's probably easier to verify compliance when compliance consists of performing a positive behavior (i.e. paying healthcare providers to do certain treatments; whatever the details of the payment, the important thing is whether the treatment was performed) instead of a negative behavior (i.e. not selling extra product at a lower price on the side). It doesn't seem obvious that this would make price-fixing much easier than it currently is.
- yread 8y agoFrom a more general pricing perspective: how should you price your product versus the status quo? Is it really appealing if it's only 10% cheaper? For my SaaS I was aiming more at 50% cheaper. Am I leaving money on the table?
- Brakenshire 8y agoIt’s a bit different to have a product which is demonstrated as better in a massive, independently audited, randomized control trial.
- refurb 8y agoThere is a whole specialized field of pricing. The answer is it depends. And even then there are often multiple “correct” strategies.
- empath75 8y agoLetting people die is even cheaper.
- hycaria 8y agoYeah I really don't get enabling the outrageously expensive carrying of genetic diseases such as SMA, especially at a time where prenatal screening can be done.
- Not_a_pizza 8y agoThe expectation I have is that these sky high prices will drive a boom not unlike the computer electronics boom of the 60's. When money of this amount is at stake, people are willing to do almost anything to get in on the action.